Search results for "catalog"

showing 10 items of 1185 documents

Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-leve…

2019

Background The precise age distribution and calculated stroke risk of screen-detected atrial fibrillation (AF) is not known. Therefore, it is not possible to determine the number needed to screen (NNS) to identify one treatable new AF case (NNS-Rx) (i.e., Class-1 oral anticoagulation [OAC] treatment recommendation) in each age stratum. If the NNS-Rx is known for each age stratum, precise cost-effectiveness and sensitivity simulations can be performed based on the age distribution of the population/region to be screened. Such calculations are required by national authorities and organisations responsible for health system budgets to determine the best age cutoffs for screening programs and d…

MaleHealth ScreeningEconomicsSocial Sciences030204 cardiovascular system & hematologyVascular MedicineScreening programmeElectrocardiography0302 clinical medicineRisk FactorsHealth careAtrial FibrillationMedicine and Health SciencesMass ScreeningPublic and Occupational Health030212 general & internal medicinemedia_commonAged 80 and overRAge FactorsGeneral MedicineMiddle AgedUniversity hospitalPrognosis3. Good healthStrokeBioassays and Physiological AnalysisNeurologyHealthMedicineFemaleTraining programArrhythmiaResearch ArticleAdultCerebrovascular DiseasesCost-Effectiveness AnalysisCardiologyLibrary scienceResearch and Analysis MethodsRisk AssessmentStroke risk03 medical and health sciencesYoung AdultAge DistributionSex FactorsPopulation MetricsPredictive Value of TestsPolitical sciencemedia_common.cataloged_instanceHumansEarly careerEuropean unionIschemic StrokeAgedHealth Care PolicyPopulation Biologybusiness.industryElectrophysiological TechniquesBiology and Life SciencesNumber needed to screenEconomic AnalysisHealth CareAge GroupsPeople and PlaceseHealthPopulation GroupingsCardiac ElectrophysiologybusinessScreening Guidelines
researchProduct

Socioeconomic inequality in non-communicable diseases in Europe between 2004 and 2015: evidence from the SHARE survey

2018

Background The scope of this work was to investigate socioeconomic inequalities among European adults aged 50 or older in chronic diseases and behavioural risk factors for these diseases, namely, smoking habits, obesity and physical inactivity, between 2004 and 2015. Methods Data for this study were drawn from the Survey of Health, Ageing and Retirement (SHARE) in Europe, which is a panel database of microdata on health, socioeconomic status and social and family networks of people aged 50 years or older, covering most of the European Union. The predicted number of non-communicable diseases (NCDs) was used to estimate the concentration index and to find the contributions of determinants to …

MaleInequalitymedia_common.quotation_subjectPopulationHealth inequality non-communicable diseases SHARE wave 6 Concentration indexSocial class03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesEnvironmental healthHumansMedicinemedia_common.cataloged_instance030212 general & internal medicineEuropean unionNoncommunicable DiseaseseducationSocioeconomic statusHealth policyAgedmedia_commonAged 80 and overeducation.field_of_studybusiness.industry030503 health policy & servicesPublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseaseObesityEuropeSocial ClassSocioeconomic FactorsChronic DiseaseMarital statusFemale0305 other medical sciencebusinessForecasting
researchProduct

Additional mailing phase for FIT after a medical offer phase: The best way to improve compliance with colorectal cancer screening in France

2017

International audience; Background: Compliance with colorectal cancer screening is critical to its effectiveness. The organisation of the mass screening programme in France has recently been modified with no evaluation of the consequences.Aims: To evaluate the impact of the way the screening test is delivered on compliance.Patients and Methods: During the first six months of the screening campaign (Ille-Vilaine, Brittany), general practitioners were asked to propose a faecal immunochemical test (FIT), OC-Sensor, to individuals at average risk for colorectal cancer (n = 152,097). A subset of non-participants in the medical phase (n = 13,071) was randomly chosen to receive a reminder that inc…

MaleMedical consultationColorectal cancer[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMass ScreeningEarly Detection of Cancermedia_commonGastroenterology[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMiddle Aged3. Good healthTest (assessment)Colorectal cancer screeningOccult Blood030220 oncology & carcinogenesisScreening[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFemale030211 gastroenterology & hepatologyFranceColorectal NeoplasmsCompliancemedicine.medical_specialtyReminder Systemseducation[SDV.CAN]Life Sciences [q-bio]/CancerCompliance (psychology)03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancermedicineHumansmedia_common.cataloged_instancePostal ServiceEuropean unionUptake rateMass screeningAgedGynecologyHepatologybusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyImmunochemical testmedicine.diseaseColorectal cancer[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieFamily medicinePatient Compliance[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessDigestive and Liver Disease
researchProduct

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

2016

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitisPediatric Infectious Disease Journal
researchProduct

The "Invisible Children": Uncertain Future of Unaccompanied Minor Migrants in Europe.

2016

Because of their particular helpless condition, the unaccompanied minor migrants are at serious risk to be further deprived of their rights, and to become de facto “invisible” to the authorities, to the public health services, and in general to the public opinion. Furthermore, when they arrive at a destination, or during their journey through Europe, many children often vanish. The full dimension of such phenomenon that further hits the unaccompanied minors along their European migration routes currently is unknown. However, the intense migration that has affected the south Mediterranean borders of the EU over the last 10 years has allowed the collection of sufficient data to raise the high…

MalePediatricsmedicine.medical_specialtyAdolescentMinor (academic)Child Abandoned03 medical and health sciencesHomeless Youth0302 clinical medicinechildren030225 pediatricsMedicinemedia_common.cataloged_instanceHumans030212 general & internal medicineEuropean unionChildmedia_commonTransients and Migrantsbusiness.industryEmigration and ImmigrationEuropeMinorsmigrantSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAPediatrics Perinatology and Child HealthEthnologyFemalebusinessunaccompained minorThe Journal of pediatrics
researchProduct

Central nervous system (CNS) cancer in children and young people in the European Union and its involvements with socio-economic and environmental fac…

2015

Malignant central nervous system (CNS) tumors are the leading cause of death by cancer in children and the second commonest pediatric cancer type. Despite several decades of epidemiologic research, the etiology of childhood CNS tumors is still largely unknown. A few genetic syndromes and therapeutic ionizing radiation are thought to account for 5-10% of childhood cancer, but the etiology of other cases remains unknown. Nongenetic causes, like environmental agents, are thought to explain them. However, as very few epidemiologic studies have been conducted, it is not surprising that nongenetic risk factors have not been detected. The biggest difference between cancers for which there are good…

MalePediatricsmedicine.medical_specialtyTime FactorsAdolescentCentral nervous systemEnvironmentCentral Nervous System NeoplasmsCohort StudiesYoung AdultRisk Factorsmedicinemedia_common.cataloged_instanceHumansYoung adultEuropean unionChildCause of deathmedia_commonbusiness.industryCancermedicine.diseasePediatric cancerEuropemedicine.anatomical_structureNeurologySocioeconomic FactorsEtiologyFemaleNeurology (clinical)businessCohort studyJournal of the neurological sciences
researchProduct

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation.

2014

Background: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. Methods: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach’s alpha.…

MalePsychometricsAparell urinariSurveys and QuestionnairesProspective cohort studyCàncermedia_commonLanguageCognitionGeneral MedicinePatient outcomeControl de qualitatNeoplasias de la Vejiga UrinariaEstudios de ValidaciónPsicometríaBufeta -- CàncerFemalePsicometriaClinical psychologyCross-Cultural ComparisonQuality of lifemedicine.medical_specialtyPsychometricsUrinary bladder neoplasms:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychological Tests::Psychometrics [Medical Subject Headings]:Publication Characteristics::Study Characteristics::Validation Studies [Medical Subject Headings]Cronbach's alpha:Disciplines and Occupations::Social Sciences::Quality of Life [Medical Subject Headings]medicine:Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms [Medical Subject Headings]media_common.cataloged_instanceHumansEuropean UnionEuropean unionAgedNeoplasm StagingGynecologyAnalysis of VarianceBladder cancerbusiness.industryResearchPublic Health Environmental and Occupational HealthConstruct validityTranslatingmedicine.diseaseCross-cultural studiesUnited StatesValidation studiesPatient outcomesCalidad de VidabusinessHealth and quality of life outcomes
researchProduct

Regulatory and academic studies to derive reference values for human health: The case of bisphenol S

2022

We would like to thank the HBM4EU team including Petra Apel (UBA), Matthieu Meslin and Christophe Rousselle (Anses) for their scientific contribution, as well as the ANSES Working Group on endocrine disruption, and its scientific Anses coordinators François Pouzaud and Sandrine Charles.; International audience; The close structural analogy of bisphenol (BP) S with BPA, a recognized endocrine-disrupting chemical and a substance of very high concern in the European Union, highlights the need to assess the extent of similarities between the two compounds and carefully scrutinize BPS potential toxicity for human health. This analysis aimed to investigate human health toxicity data regarding BPS…

MaleSwineBisphenol SPhysiologyBiological Availability010501 environmental sciencesBiologyEndocrine Disruptors01 natural sciencesBiochemistry03 medical and health scienceschemistry.chemical_compoundHuman healthPhenolsReference ValuesMESH: Policy MakingPolicy makingmedia_common.cataloged_instanceAnimalsHumansSulfonesEuropean unionBenzhydryl Compounds030304 developmental biology0105 earth and related environmental sciencesGeneral Environmental Sciencemedia_common0303 health sciencesPotential impactToxicity3. Good healthBioavailabilityMESH: Endocrine Disruptors[SDV.TOX] Life Sciences [q-bio]/ToxicologyBisphenol SchemistryReference values[SDV.TOX]Life Sciences [q-bio]/ToxicologyToxicityHealth-based guidance valueFemaleEndocrine-disrupting chemicalTarget organhormones hormone substitutes and hormone antagonists
researchProduct

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

2018

Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar efficacy, but improved safety could be achieved with 75 mg without 175 mg loading doses (ClinicaTrials.gov: NCT01180049). Patients with relapsed/refractory MCL were randomized to once-weekly temsirolimus 175/75 mg (n = 47) or 75 mg (n = 42). Treatment continued until objective disease progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs). Median PFS was 4.3 versu…

MaleTemsirolimusCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-CellGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy Protocols80 and overClinical endpointmedia_commonAged 80 and overHazard ratioHematologyMiddle AgedPrognosisTemsirolimusSurvival RateLocalOncology030220 oncology & carcinogenesisInjections IntravenousRefractory Mantle Cell LymphomaFemaleIntravenousmedicine.drugsafetymedicine.medical_specialtyoverall survivalmantle cell lymphomaAntineoplastic AgentsDrug Administration ScheduleInjections03 medical and health sciencesRefractoryInternal medicinemedicineHumansmedia_common.cataloged_instanceProgression-free survivalEuropean unionAgedSirolimusSalvage Therapybusiness.industryMantle-Cellmedicine.diseaseSurgeryNeoplasm RecurrenceDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusinessprogression-free survivalFollow-Up Studies030215 immunology
researchProduct

2011–12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hos…

2013

BackgroundInfluenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. Large sample size is needed to have precise estimate of influenza vaccine effectiveness (IVE) against severe outcomes. We assessed the feasibility of measuring seasonal IVE against hospitalisation with laboratory confirmed influenza through a network of 21 hospitals in the European Union.MethodsWe conducted a multicentre study in France (seven hospitals), Italy (one hospital), and Navarra (four hospitals) and Valencia (nine hospitals) regions in Spain. All ≥1…

MaleViral DiseasesEpidemiologyPilot ProjectsLogistic regressionmedicine.disease_cause0302 clinical medicineInfluenza A virusClinical Epidemiology030212 general & internal medicineEpidemiological Methodsmedia_commonAged 80 and overeducation.field_of_studyVaccinesMultidisciplinaryQVaccinationREpidemiology of AgingMiddle Aged3. Good healthVaccinationHospitalizationInfectious DiseasesInfluenza VaccinesMedicineFemaleSeasonsResearch ArticleAdultmedicine.medical_specialtyAdolescentInfluenza vaccineClinical Research DesignScience030231 tropical medicinePopulationMicrobiologyHistory 21st CenturyInfectious Disease Epidemiology03 medical and health sciencesYoung AdultInternal medicineVirologyVaccine DevelopmentInfluenza Humanmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationBiologyAgedbusiness.industryInfluenza A Virus H3N2 SubtypeCase-control studyImmunityViral VaccinesInfluenzaSample size determinationCase-Control StudiesImmunologyClinical ImmunologybusinessPLoS ONE
researchProduct